Search | Clinical Trials Finder

Conditions: Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions: Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 4 Years to 7 Years
Enrollment: 882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 26
States / cities: Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more

Conditions: Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Meningococcal Meningitis
Interventions: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine; Biological
Lead sponsor: Novartis; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • Fremont, California • Madera, California + 14 more

Conditions: Meningococcal Vaccine
Interventions: MenABCWY, Saline, rLP2086, MenACWY-CRM; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more

Conditions: Meningococcal Meningitis, Meningococcal Infections
Interventions: NmVac4-A/C/Y/W-135-DT™; Biological
Lead sponsor: JN-International Medical Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Meningococcal Disease, Infections, Meningococcal
Interventions: MenACWY-CRM; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Lake Mary, Florida + 15 more

Conditions: Meningococcal Infections, Meningitis
Interventions: Menactra®, Menomune®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 14 Years to 27 Years
Enrollment: 763 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more

Conditions: Prevention of Meningococcal Disease
Interventions: MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY-CRM conjugate vaccine, unadjuvanted, MenACWY polysaccharide vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 524 participants
Timeline: 2004 – 2006
U.S. locations: 3
States / cities: Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Meningococcal Meningitis
Interventions: MenACWY-CRM conjugate vaccine, Licensed comparator; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 32
States / cities: Birmingham, Alabama • Fremont, California • Fresno, California + 21 more

Conditions: Meningitis, Meningococcal Infection
Interventions: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 365 Days
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more

Conditions: Meningitis, Meningococcal, Serogroup B
Interventions: rLP2086; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Meningitis, Meningococcal Infection
Interventions: Polysaccharide Diphtheria Conjugate Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 7 Years to 15 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Marietta, Georgia + 8 more

Conditions: Meningitis, Meningococcemia
Interventions: Meningococcal polysaccharide diphtheria toxoid conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years to 6 Years
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Marietta, Georgia • Woodstock, Georgia • Bardstown, Kentucky + 9 more

Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions: Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®, Prevnar 13®, PedvaxHIB®, Havrix®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 and Gardasil, rLP2086, Gardasil; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 2,499 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 87
States / cities: Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 12 Months
Enrollment: 1,378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 78
States / cities: Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more

Conditions: Meningococcal Meningitis, Meningococcal Infections
Interventions: Test Vaccine, US Licensed Vaccine; Biological
Lead sponsor: JN-International Medical Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Greenbelt, Maryland • Pasadena, Maryland • Towson, Maryland

Conditions: Gonorrhoea
Interventions: Meningococcal Group B Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions: MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 22 Months to 60 Months
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 21
States / cities: Little Rock, Arkansas • Fountain Valley, California • Norwich, Connecticut + 15 more

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 19 Months
Enrollment: 950 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 45
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK 134612, Menactra®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Chandler, Arizona • Paramount, California • Sacramento, California + 19 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 15 Months
Enrollment: 4,441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 88
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 4,021 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more

Conditions: Meningitis, Meningococcal
Interventions: MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more

Search by objective public record fields.

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine